NHPD Monthly Communiqué

Similar documents
Questions or comments regarding the content of the NHPD Monthly Communiqué may be addressed to

M I L L E R T H O M S O N LLP Barristers & Solicitors, Patent & Trade Mark Agents

COMPENDIUM OF MONOGRAPHS NATURAL HEALTH PRODUCTS DIRECTORATE

Questions or comments regarding the content of the NHPD Monthly Communiqué may be addressed to

Guidance Document The Use of Probiotic Microorganisms in Food

THE NEW CANADIAN NATURAL HEALTH PERODUCT REGULATIONS

Natural Health Product Raw Material Policy

Classification of Products at the Food Natural Health Product Interface: Products in Food Formats

INTERIM NOTIFICATION PROGRAM LOW RISK VETERINARY HEALTH PRODUCTS OVERVIEW

Health Canada s Safety Assessment Process for Sugar Substitutes

Recall Guidelines. for Chinese Medicine Products

Bill C-51 and Natural Health Products - The Facts

Health Canada Proposes New Rules to Regulate NHPs Like Drugs

Food and Drug Regulations - Project Number Schedule F

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.

Food Labeling: Policy Rationale IFT Food Policy Impact, 2011

The Marketing of a Food Ingredient Understanding a System that has Worked for 105 Years

Archived Content. This content was archived on June 24, 2013.

Health Canada s Proposed Approach to Managing Caffeinated Energy Drinks

Canadian Grain Commission

December 4, 2017 VIA ELECTRONIC SUBMISSION

Medical Devices. BARBADOS Clarke Gittens Farmer

Food Directorate Update: Supplemented Foods and Nutrition Labelling

FDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update

TOBACCO PRODUCT OR MEDICAL PRODUCT?

Psyllium Products and Blood Cholesterol Lowering

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

Classification of Products at the Cosmetic-Drug Interface

Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;

Food Fortification Regulations, 2016 (Gazetted on 24 October, 2016) ARRANGEMENT OF SECTIONS PART I PRELIMINARY

CENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER: Orig1s000 APPROVAL LETTER

Issuance of the final Consumer Advertising Guidelines for Marketed Health Products (for Nonprescription Drugs including Natural Health Products)

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

NDA NDA APPROVAL

An update on the regulatory framework for labelling across the EU Dr David Jukes Department of Food and Nutritional Sciences University of Reading

Category Specific Guidance for Temporary Marketing Authorization: Supplemented Food. February 2016

Archived Content. This content was archived on June 24, 2013.

Guidance for Municipalities Regarding Marijuana for Adult Use January 2018

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044

The Clean Environment Commission. Public Participation in the Environmental Review Process

RE: Permits under the Arizona Pharmacy Act should not be required for dietary supplements

Informationsbeauftragter und Arzneimittelwerbung / Person designated responsible for information and advertising of medicinal products

Dietary Supplement Health and Education Act of 1994 Public Law rd Congress

Use of Light, Mild, Low, or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products

PREFACE. Saskatchewan is participating in the Common Drug Review (CDR).

AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)

AUSTRALIAN MADE CAMPAIGN LIMITED

The Nutrition and Health Claims Regulation

Re: Bill S-5, An Act to amend the Tobacco Act and the Non-smokers Health Act and to make consequential amendments to other Acts

Interim Policy on the Use of Expired Interim Marketing Authorizations Related to Food Fortification

Nutritional Information and the Food Information Regulations John Stewart

COMMISSION REGULATION (EU)

Cannabis Retail Regulation and Licence Applications PART 1 NOVEMBER 27, 2018

CIGARETTE FIRE SAFETY AND FIREFIGHTER PROTECTION ACT Act of Jul. 4, 2008, P.L. 518, No. 42 Cl. 35 AN ACT

Regulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices

Enforcement Policy Statement on Marketing Claims for OTC Homeopathic Drugs

April 30, By Electronic Mail

Please find enclosed Dosimetry Service Licence No which replaces Dosimetry Service Licence No

Food Labelling in Canada

Cannabis Regulation in Canada:

PLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.

H 5501 S T A T E O F R H O D E I S L A N D

Update on the Canadian Food Inspection Agency (CFIA) Food Labelling Modernization Initiative

Cannabis Retail Store Licensing in Ontario. General Committee December 10, 2018

MEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA

CHAPTER 64B5-12 CONTINUING PROFESSIONAL EDUCATION

B.C. Cannabis PRIVATE RETAIL LICENSING GUIDE Applications and Operations

Submission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No.

COUNCIL OF THE EUROPEAN UNION. Brussels, 7 September 2009 (OR. en) 11261/09 Interinstitutional File: 2008/0002 (COD) DENLEG 51 CODEC 893

QUESTIONS AND ANSWERS Access to Drugs in Exceptional Circumstances

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products

5.I.1. GENERAL PRACTITIONER ANNOUNCEMENT OF CREDENTIALS IN NON-SPECIALTY INTEREST AREAS

MODIFICATION OF APPLICATION TO BECOME A LICENSED PRODUCER UNDER THE ACCESS TO CANNABIS FOR MEDICAL PURPOSES REGULATIONS

Understanding the New Access to Cannabis for Medical Purposes Regulations

Kansas Department of Revenue. September 22, Revenue Ruling No

Session Overview. Session Objectives. Location of Information on Labels. What is required on all labels? 5/21/2013

on the advertising of medicinal products for human use

Requirements to the Registration of Medicinal products in the Republic of Armenia

Details of Authorised Personnel

3.0 Approval of the minutes March 6, 2011 The minutes were approved as circulated electronically to Committee members and posted on the NAPRA website.

The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))

2014 UPDATED YOLO COUNTY CODE. Title 8 LAND DEVELOPMENT CHAPTER 6: ALCOHOLIC BEVERAGE CONTROL ORDINANCE

The North American Metal Packaging Alliance

Guidance Document. 9 May A guidance document issued by the Ministry for Primary Industries

PROPOSED REGULATION OF THE BOARD OF HEARING AID SPECIALISTS. LCB File No. R July 6, 2001

DEPARTMENT OF HEALTH & HUMAN SERVICES

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

Government Gazette REPUBLIC OF SOUTH AFRICA

Code sections 4(1)(b), 4(2)(a), 4(2)(c), 4(2)(e)(ii) Withdrawal of advertisement. Withdrawal of representations

LEAF Marque Assurance Programme

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

HISTORY, CAPACITY AND POSITION

ACTION: Notification; declaratory order; extension of compliance date.

OUR COMMITMENT OPEN DIALOGUE & DEBATE COMMITMENT TO EDUCATION

Counterfeit Medicinal Products. FINLAND Roschier, Attorneys Ltd.

The Cannabis Control (Saskatchewan) Regulations

Interchangeable Drug Products - Additional Criteria

Commentary Pharmacopeial Forum 34(2) March-April 2008 Interim Revision Announcements to USP 30-NF 25 Revised June 30, 2008

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015

Title of Session: Restricting the Marketing and Advertising of Opioids in Canada Date of Session: September 5, 2018

Transcription:

NHPD Monthly Communiqué Vol. 3, Issue 5 February 2008 The NHPD Monthly Communiqué is a publication of Health Canada s Natural Health Products Directorate (NHPD), the federal department responsible for the regulation of natural health products sold in Canada. The communiqué is released to the Canadian public each month via the NHPD's electronic bulletin. Subscribe to the NHPD e-bulletin at: www.healthcanada.gc.ca/nhpd_bulletin. Questions or comments regarding the content of the NHPD Monthly Communiqué may be addressed to NHPD_DPSN@hc-sc.gc.ca. TABLE OF CONTENT PRODUCT LICENSING INFORMATION:...2 New and Revised Natural Health Product Monographs...2 Advertising Claims on Label Texts for Natural Health Products...4 REVISIONS Important Tips and Recommendations for Assembling a Product Licence Application Package...4 New Guidance Document Post Licensing Guidance Document...5 Revised Guidance Document Application for International Trade Certificate for Natural Health Products...6 SITE LICENSING INFORMATION:...6 COMPLIANCE CORNER:...6 Compliance Date for Priority 5 Natural Health Products...6 CLINICAL TRIAL INFORMATION:...7 POLICY AND REGULATORY AFFAIRS:...7 RESEARCH INFORMATION:...7 OTHER INFORMATION:...7 Expert Advisory Committee (EAC) - Update...7 1

PRODUCT LICENSING INFORMATION: New and Revised Natural Health Product Monographs Recognizing the important role monographs can play both in facilitating the review and processing of product licence applications and as reliable sources of product information for consumers, the NHPD is committed to developing new monographs as well as revising and updating existing monographs to reflect new research and evidence. New Single Ingredient Monographs 5-HTP Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_5-htp_e.html Coenzyme Q 10 Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_coenz-q10_e.html Thiamine Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_thiamine_e.html Applicants that have already submitted a non-compendial product licence application for one of the substances listed above are encouraged to reclassify their application as a compendial product licence application, citing the corresponding monograph. Instructions on how to reclassify an application are available in the July 2007 issue of the NHPD Monthly Communiqué (http://www.hc-sc.gc.ca/dhpmps/prodnatur/bulletins/_communiques/communique_july07_e.html#1_1) Revised Single Ingredient Monographs Angelica Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_angelicaangelique_e.html Astragalus Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_astragalusastragale_e.html Avens Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_avens-benoite_e.html Bilberry Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_bilberry-myrtille_e.html Boldo Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_boldo_e.html Burdock Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_burdockbardane_e.html Caffeine Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_caffe-cafe_e.html 2

Cranberry Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_cranberrycanneberge_e.html Cayenne Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_cayenne_e.html Dandelion Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_dandelionpissenlit_e.html Evening Primrose Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_primrose-onagre_e.html Figwort Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_figwortscrofulaire_e.html Fish Oil Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licenprod/monograph/mono_fish_oil_huile_poisson_e.html Flax Monograph: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licenprod/monograph/mono_flax-lin_e.html Ginger Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_gingergingembre_e.html Lysine Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_lysine_e.html Mugwort Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_mugwortarmoisecommune_e.html Pantothenic Acid Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_pantothenic_e.html Seal Oil Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licenprod/monograph/mono_seal_oil_huile_phoque_e.html Skullcap Monograph: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/monograph/mono_scullcapscutellaire_e.html Product licence holders of natural health products previously licensed under the old versions of the single ingredient listed above are encouraged to commission new labels that comply with the revised monographs as soon as possible. As per section 11 of the Natural Health Products Regulations, an amendment with the revised information must 3

be filed with and approved by the NHPD before proceeding with the new label run. Applicants should note that any submissions in queue are required to attest to the revised monographs. Advertising Claims on Label Texts for Natural Health Products The purpose of this article is to clarify the review of advertising claims in proposed label texts by the Natural Health Products Directorate (NHPD). The NHPD reviews proposed label texts as per the labelling requirements set out in Part 5 of the Natural Health Products Regulations. Part 5 does not outline any requirements with respect to advertising claims and as such, the NHPD will no longer review advertising claims indicated on the label texts. Applicants are responsible for ensuring that advertising claims on the labels of their products do not contravene Section 9 of the Food and Drugs Act. Section 9(1) of the Food and Drugs Act states that No person shall label, package, treat, process, sell or advertise any drug in a manner that is false, misleading or deceptive or is likely to create an erroneous impression regarding its character, value, quantity, composition, merit or safety. Advertising claims will not be reviewed during assessment with the exception of comparative claims and clinically proven/tested claims. The NHPD may request additional evidence to support comparative and clinically proven/tested claims. Furthermore, compendial applications with comparative claims that require additional evidence may see their applications transferred to the non-traditional assessment stream. If the claim is removed, the application can remain in the compendial assessment stream. Information specific to acceptable advertising claims, including comparative claims and clinically proven/tested claims, can be obtained from the guidance document Consumer Advertising Guidelines for Marketed Health Products for Nonprescription Drugs including Natural Health Products, which is available at: http://www.hc-sc.gc.ca/dhp-mps/advert-publicit/pol/guide-ldir_consom_consum_e.html. This document provides guidance to industry and stakeholders so that they can meet the provisions of the Food and Drugs Act and its Regulations. REVISIONS Important Tips and Recommendations for Assembling a Product Licence Application Package The Natural Health Products Directorate (NHPD) has modified its tips and recommendations for assembling a Product Licence Application (PLA) package. These revised recommendations replace those previously published in the Vol. 2, Issue 5 - February 2007 of the NHPD Monthly Communiqué and currently found in Chapter 3.1 of the Product Licensing Guidance Document. Tips and Recommendations 4

Applicants are now only required to provide one copy of the submission package for each PLA and not two copies as previously recommended. PLAs should continue to be typed, submitted by mail/courier, and contain original signatures. In light of this revision, duplicate copies sent to the NHPD will not be associated with the submission file and will be discarded upon receipt. To ensure that PLAs can be processed quickly and efficiently, the NHPD has the following additional tips and recommendations it strongly encourages applicants to follow. Compliance with these recommendations will accelerate the issuance of acknowledgement letters: Supporting documents included with the PLA should not be stapled, coiled, or bound. Elastic bands and/or large presentation clips should be used to hold documents together. The use of dividers, binders, duo-tangs is not recommended. They will be discarded upon receipt. All documents should be double-hole punched at the top of the document and organized in the following order: 1. Cover Letter 2. Letter of Access (if applicable) 3. Completed PLA Form 4. Designated Party Authorization Form (if applicable) 5. Animal Tissue Form (if applicable) 6. NHP Label Text 7. Drug Label Text (if applicable, in the case of products previously licensed as drugs and issued DINs) 8. Quality Summary Report including finished product specifications (if applicable) 9. Evidence Summary Report (if applicable) 10. Safety Summary Report (if applicable) 11. References (if applicable)\ New Guidance Document Post Licensing Guidance Document Once a Natural Health Product (NHP) has been granted a Natural Product Number (NPN, or DIN-HM for homeopathic medicines), it is not uncommon for licensees to make changes to the product; such changes are referred to as post-licensing changes. The Post Licensing Guidance Document provides information on the different types of post licensing changes as well as recommendations for licencees on how to submit the required documentation to Health Canada. This new guidance document is available online at: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/licen-prod/docs/plgd_psdldr_e.html 5

Revised Guidance Document Application for International Trade Certificate for Natural Health Products The Natural Health Products Directorate (NHPD) has made the following addition to Chapter 3.3. of the Application for International Trade Certificate for Natural Health Products guidance document: When requested to issue an International Trade Certificate, the Natural Health Products Directorate will also consider any current compliance and enforcement action being taken against the product, site or applicant in question. The revised document is available online at: http://www.hc-sc.gc.ca/dhpmps/prodnatur/applications/int-certificat/doc/itc_cci-pol_e.html SITE LICENSING INFORMATION: No new information to report this month. COMPLIANCE CORNER: Compliance Date for Priority 5 Natural Health Products On January 10, 2008, the Natural Health Products Directorate (NHPD) released an important notice reminding stakeholders that the compliance date for Priority 5 natural health products (NHPs) has passed (January 1, 2008). Priority 5 NHPs include vitamins and minerals. In accordance with the Compliance Policy for Natural Health Products, Priority 5 NHPs that present an unacceptable risk to health or that have not been issued a submission number by January 1, 2008, will be subject to compliance action, which may include the removal of all Priority 5 NHPs from the Canadian market as well as the refusal of incoming shipments of Priority 5 NHPs. Compliance and enforcement actions will be carried out by the Health Products and Food Branch Inspectorate (HPFBI) in accordance with the Compliance and Enforcement Policy (POL 0001). A copy of the January 10, 2008 notice is available online at: http://www.hc-sc.gc.ca/dhpmps/prodnatur/bulletins/compliance-conformite_mess5_e.html 6

CLINICAL TRIAL INFORMATION: No new information to report this month. POLICY AND REGULATORY AFFAIRS: No new information to report this month. RESEARCH INFORMATION: No new information to report this month. OTHER INFORMATION: Expert Advisory Committee (EAC) - Update Further to the Open Call for Nominations issued in June 2007 for an expert in herbalism/ nutrition, the NHPD has completed its selection process and is pleased to announce the addition of Amanda Howe to the Expert Advisory Committee (EAC) on Natural Health Products Amanda Howe will be joining current EAC members Dr. Heather Boon (co-chair of the EAC), Dr. Joseph Betz, Dr. John Thor Aranson, Dr. David Lescheid, Dr. David Brule, Dr. Leonard Piché, Ron Rosenes, Dr. Ikhlas Khan, Dr. Mary Hardy, Dr. Fereidoon Shahidi, Dr. Colin Barrow, Dr. Francis Law and Dr. Michael Chung. The EAC is an external group composed of approximately 10 to 14 non-governmental scientists and professionals with extensive knowledge and expertise in a variety of fields, including naturopathy, homeopathy, traditional Chinese medicine, Aboriginal medicine, chemistry, biology, pharmacology, nutrition, and toxicology. Its role is to provide the NHPD with advice and guidance on questions pertaining to the safety, quality, efficacy, claims use, and regulation of natural health products in Canada. The open call process in general was extremely successful, with over 20 nominations submitted for consideration. The Directorate is indeed encouraged to see such a vast interest in the science and regulation of natural health products in Canada. 7

In closing, the NHPD would also like to take this opportunity to thank the departing member of the EAC, Gillian Leverkus. Ms Leverkus, has been involved with Health Canada for several years, participating on a number of natural health product working groups and committees. Her contributions over the years have been invaluable to the Natural Health Products Directorate. The NHPD wishes Ms. Leverkus the best of luck in her future endeavours. 8